Mechanisms of impaired differentiation in rhabdomyosarcoma

FEBS Journal

Volumn 280, Issue 17, 2013, Pages 4323-4334

  Keller, Charles ^a   Guttridge, Denis C ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

differentiation; microRNA; MyoD; myogenesis; rhabdomyosarcoma; signaling

Indexed keywords

BIOLOGICAL MARKER; CELL PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; HISTONE DEMETHYLASE; HISTONE DEMETHYLASE JARID2; HISTONE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE KMT1A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4 RECEPTOR; MICRORNA; MICRORNA 206; MICRORNA 29; MITOGEN ACTIVATED PROTEIN KINASE; MUSCULIN; MYOD PROTEIN; MYOGENIN; MYOSTATIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN KINASE B; PROTEIN P53; PROTEIN P73; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME 1; CHROMOSOME 2; CHROMOSOME TRANSLOCATION; DISEASE COURSE; DOWN REGULATION; EPIGENETICS; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; LIMB PERFUSION; LIMB SALVAGE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR SUPPRESSOR GENE;

DIFFERENTIATION; MICRORNA; MYOD; MYOGENESIS; RHABDOMYOSARCOMA; SIGNALING;

ANIMALS; CELL DIFFERENTIATION; HUMANS; MUSCLE, SKELETAL; RHABDOMYOSARCOMA;

EID: 84882646556     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12421     Document Type: Review

References (117)

1. Ries LAG, Smith MA, Gurney JG, et al,. (1999) Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. NIH Pub NCI SEER Program 99, 4649.
2. Perez EA, et al,. (2011) Rhabdomyosarcoma in children: a SEER population based study. J Surg Res 170, e243-251.
3. Punyko JA, et al,. (2005) Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer 103, 1475-1483.
4. Punyko JA, et al,. (2005) Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study. Pediatr Blood Cancer 44, 643-653.
5. Xia SJ, Pressey JG, &, Barr FG, (2002) Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 1, 97-104.
6. Dias P, et al,. (2000) Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol 156, 399-408.
7. Sebire NJ, &, Malone M, (2003) Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. J Clin Pathol 56, 412-416.
8. Tonin PN, Scrable H, Shimada H, &, Cavenee WK, (1991) Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res 51, 5100-5106.
9. Hatley ME, et al,. (2012) A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell 22, 536-546.
10. Gurney JG, (1999) Topical topics: brain cancer incidence in children: time to look beyond the trends. Med Pediatr Oncol 33, 110-112.
11. Barr FG, (1997) Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 19, 483-491.
12. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, &, Barr FG, (1994) Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 54, 2869-2872.
13. Galili N, et al,. (1993) Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 5, 230-235.
14. Lam PY, Sublett JE, Hollenbach AD, &, Roussel MF, (1999) The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Mol Cell Biol 19, 594-601.
15. Scheidler S, Fredericks WJ, Rauscher FJ 3rd, Barr FG, &, Vogt PK, (1996) The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc Natl Acad Sci USA 93, 9805-9809.
16. Anderson J, Ramsay A, Gould S, &, Pritchard-Jones K, (2001) PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol 159, 1089-1096.
17. Keller C, et al,. (2004) Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 18, 2614-2626.
18. Bennicelli JL, Advani S, Schafer BW, &, Barr FG, (1999) PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene 18, 4348-4356.
19. Fredericks WJ, et al,. (1995) The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 15, 1522-1535.
20. Davis RJ, &, Barr FG, (1997) Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA 94, 8047-8051.
21. Barr FG, et al,. (1996) In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Hum Mol Genet 5, 15-21.
22. Miller PJ, &, Hollenbach AD, (2007) The oncogenic fusion protein Pax3-FKHR has a greater post-translational stability relative to Pax3 during early myogenesis. Biochim Biophys Acta 1770, 1450-1458.
23. Brunet A, et al,. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868.
24. del Peso L, Gonzalez VM, Hernandez R, Barr FG, &, Nunez G, (1999) Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene 18, 7328-7333.
25. Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ 3rd, &, Schafer BW, (1996) Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci USA 93, 13164-13169.
26. Margue CM, Bernasconi M, Barr FG, &, Schafer BW, (2000) Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR. Oncogene 19, 2921-2929.
27. Armeanu-Ebinger S, et al,. (2011) Differential expression of invasion promoting genes in childhood rhabdomyosarcoma. Int J Oncol 38, 993-1000.
28. Khan J, et al,. (1999) cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA 96, 13264-13269.
29. Khan J, et al,. (1998) Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 58, 5009-5013.
30. Mercado GE, et al,. (2008) Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosom Cancer 47, 510-520.
31. Schaaf GJ, et al,. (2005) Full transcriptome analysis of rhabdomyosarcoma, normal, and fetal skeletal muscle: statistical comparison of multiple SAGE libraries. FASEB J 19, 404-406.
32. Wachtel M, et al,. (2004) Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 64, 5539-5545.
33. Kikuchi K, et al,. (2008) Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun 365, 568-574.
34. Galindo RL, Allport JA, &, Olson EN, (2006) A Drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR. Proc Natl Acad Sci USA 103, 13439-13444.
35. Keller C, Hansen MS, Coffin CM, &, Capecchi MR, (2004) Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 18, 2608-2613.
36. Lassar AB, et al,. (1991) Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell 66, 305-315.
37. Tapscott SJ, Thayer MJ, &, Weintraub H, (1993) Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 259, 1450-1453.
38. McAllister RM, Melnyk J, Finkelstein JZ, Adams EC Jr, &, Gardner MB, (1969) Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer 24, 520-526.
39. Yang Z, et al,. (2009) MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. Genes Dev 23, 694-707.
40. Puri PL, &, Sartorelli V, (2000) Regulation of muscle regulatory factors by DNA-binding, interacting proteins, and post-transcriptional modifications. J Cell Physiol 185, 155-173.
41. Sartorelli V, &, Puri PL, (2001) The link between chromatin structure, protein acetylation and cellular differentiation. Front Biosci 6, D1024-1047.
42. Mal AK, (2006) Histone methyltransferase Suv39h1 represses MyoD-stimulated myogenic differentiation. EMBO J 25, 3323-3334.
43. Lee MH, Jothi M, Gudkov AV, &, Mal AK, (2011) Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state. Cancer Res 71, 3921-3931.
44. Mungamuri SK, et al,. (2012) p53-mediated heterochromatin reorganization regulates its cell fate decisions. Nat Struct Mol Biol 19, 478-484.
45. Felix CA, et al,. (1992) Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 52, 2243-2247.
46. Takahashi Y, et al,. (2004) Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod Pathol 17, 660-669.
47. Rota R, Ciarapica R, Giordano A, Miele L, &, Locatelli F, (2011) MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality. Mol Cancer 10, 120-135.
48. McCarthy JJ, (2008) MicroRNA-206: the skeletal muscle-specific myomiR. Biochim Biophys Acta 1779, 682-691.
49. Elbashir SM, et al,. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
50. Rao PK, Kumar RM, Farkhondeh M, Baskerville S, &, Lodish HF, (2006) Myogenic factors that regulate expression of muscle-specific microRNAs. Proc Natl Acad Sci USA 103, 8721-8726.
51. Sweetman D, et al,. (2008) Specific requirements of MRFs for the expression of muscle specific microRNAs, miR-1, miR-206 and miR-133. Dev Biol 321, 491-499.
52. Chen JF, et al,. (2010) microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. J Cell Biol 190, 867-879.
53. Dey BK, Gagan J, &, Dutta A, (2011) miR-206 and -486 induce myoblast differentiation by downregulating Pax7. Mol Cell Biol 31, 203-214.
54. Gagan J, Dey BK, Layer R, Yan Z, &, Dutta A, (2012) Notch3 and Mef2c proteins are mutually antagonistic via Mkp1 protein and miR-1/206 microRNAs in differentiating myoblasts. J Biol Chem 287, 40360-40370.
55. Kim HK, Lee YS, Sivaprasad U, Malhotra A, &, Dutta A, (2006) Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol 174, 677-687.
56. Rosenberg MI, Georges SA, Asawachaicharn A, Analau E, &, Tapscott SJ, (2006) MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206. J Cell Biol 175, 77-785.
57. Li L, Sarver AL, Alamgir S, &, Subramanian S, (2012) Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. Lab Invest 92, 571-583.
58. Rao PK, et al,. (2010) Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J 24, 3427-3437.
59. Taulli R, et al,. (2009) The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 119, 2366-2378.
60. Yan D, et al,. (2009) MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 284, 29596-29604.
61. Missiaglia E, et al,. (2010) MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas. Br J Cancer 102, 1769-1777.
62. Macquarrie KL, Yao Z, Young JM, Cao Y, &, Tapscott SJ, (2012) miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells. Skelet Muscle 2, 7.
63. Macquarrie KL, et al,. (2013) Comparison of genome-wide binding of MyoD in normal human myogenic cells and rhabdomyosarcomas identifies regional and local suppression of promyogenic transcription factors. Mol Cell Biol 33, 773-784.
64. Allen RE, Sheehan SM, Taylor RG, Kendall TL, &, Rice GM, (1995) Hepatocyte growth factor activates quiescent skeletal muscle satellite cells in vitro. J Cell Physiol 165, 307-312.
65. McKinsey TA, Zhang CL, Lu J, &, Olson EN, (2000) Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 408, 106-111.
66. Goljanek-Whysall K, et al,. (2012) Regulation of multiple target genes by miR-1 and miR-206 is pivotal for C2C12 myoblast differentiation. J Cell Sci 125, 3590-3600.
67. Epstein JA, Lam P, Jepeal L, Maas RL, &, Shapiro DN, (1995) Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 270, 11719-11722.
68. Davicioni E, et al,. (2006) Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 66, 6936-6946.
69. Cao L, et al,. (2010) Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 70, 6497-6508.
70. Crose LE, et al,. (2012) FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 18, 3780-3790.
71. Lagha M, et al,. (2008) Pax3 regulation of FGF signaling affects the progression of embryonic progenitor cells into the myogenic program. Genes Dev 22, 1828-1837.
72. Engert JC, Berglund EB, &, Rosenthal N, (1996) Proliferation precedes differentiation in IGF-I-stimulated myogenesis. J Cell Biol 135, 431-440.
73. Epstein JA, Shapiro DN, Cheng J, Lam PY, &, Maas RL, (1996) Pax3 modulates expression of the c-Met receptor during limb muscle development. Proc Natl Acad Sci USA 93, 4213-4218.
74. Ferracini R, et al,. (1996) Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene 12, 1697-1705.
75. Ginsberg JP, Davis RJ, Bennicelli JL, Nauta LE, &, Barr FG, (1998) Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res 58, 3542-3546.
76. Phelan SA, &, Loeken MR, (1998) Identification of a new binding motif for the paired domain of Pax-3 and unusual characteristics of spacing of bipartite recognition elements on binding and transcription activation. J Biol Chem 273, 19153-19159.
77. Cornelison DD, &, Wold BJ, (1997) Single-cell analysis of regulatory gene expression in quiescent and activated mouse skeletal muscle satellite cells. Dev Biol 191, 270-283.
78. Miekus K, et al,. (2013) The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation. Cell Death Dis 4, e459.
79. Walters ZS, et al,. (2013) JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene. doi: 10.1038/onc.2013.46.
80. Klose RJ, Kallin EM, &, Zhang Y, (2006) JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet 7, 715-727.
81. Shen X, et al,. (2009) Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. Cell 139, 1303-1314.
82. Calhabeu F, Hayashi S, Morgan JE, Relaix F, &, Zammit PS, (2013) Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells. Oncogene 32, 651-662.
83. Hosoyama T, et al,. (2011) IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma. Clin Cancer Res 17, 2757-2766.
84. Nanni P, et al,. (2009) Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. Mol Cancer Ther 8, 754-761.
85. Mauro A, et al,. (2002) PKCalpha-mediated ERK, JNK and p38 activation regulates the myogenic program in human rhabdomyosarcoma cells. J Cell Sci 115, 3587-3599.
86. Puri PL, et al,. (2000) Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev 14, 574-584.
87. Palacios D, et al,. (2010) TNF/p38alpha/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 7, 455-469.
88. Serra C, et al,. (2007) Functional interdependence at the chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle differentiation. Mol Cell 28, 200-213.
89. Lejeune FJ, et al,. (2000) Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 26, 669-678.
90. Han HQ, &, Mitch WE, (2011) Targeting the myostatin signaling pathway to treat muscle wasting diseases. Curr Opin Support Palliat Care 5, 334-341.
91. Lee SJ, (2004) Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20, 61-86.
92. Rossi S, Stoppani E, Puri PL, &, Fanzani A, (2011) Differentiation of human rhabdomyosarcoma RD cells is regulated by reciprocal, functional interactions between myostatin, p38 and extracellular regulated kinase signalling pathways. Eur J Cancer 47, 1095-1105.
93. Langley B, et al,. (2004) Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway. Oncogene 23, 524-534.
94. Ricaud S, et al,. (2003) Inhibition of autocrine secretion of myostatin enhances terminal differentiation in human rhabdomyosarcoma cells. Oncogene 22, 8221-8232.
95. Ozes ON, et al,. (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401, 82-85.
96. Romashkova JA, &, Makarov SS, (1999) NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401, 86-90.
97. Sizemore N, Leung S, &, Stark GR, (1999) Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 19, 4798-4805.
98. Trendelenburg AU, Meyer A, Jacobi C, Feige JN, &, Glass DJ, (2012) TAK-1/p38/nNFkappaB signaling inhibits myoblast differentiation by increasing levels of activin A. Skelet Muscle 2, 3.
99. Guttridge DC, Albanese C, Reuther JY, Pestell RG, &, Baldwin AS Jr, (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19, 5785-5799.
100. Guttridge DC, Mayo MW, Madrid LV, Wang C-Y, &, Baldwin AS Jr, (2000) NF-kB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289, 2363-2366.
101. Peterson JM, Bakkar N, &, Guttridge DC, (2011) NF-kappaB signaling in skeletal muscle health and disease. Curr Top Dev Biol 96, 85-119.
102. Wang H, et al,. (2008) NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 14, 369-381.
103. Wang H, et al,. (2007) NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol 27, 4374-4387.
104. Mayo MW, et al,. (2002) PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem 277, 11116-11125.
105. Webster GA, &, Perkins ND, (1999) Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol 19, 3485-3495.
106. Cam H, et al,. (2006) p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 10, 281-293.
107. Meddeb M, et al,. (1996) MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). Cytogenet Cell Genet 73, 325-330.
108. Fiddler TA, Smith L, Tapscott SJ, &, Thayer MJ, (1996) Amplification of MDM2 inhibits MyoD-mediated myogenesis. Mol Cell Biol 16, 5048-5057.
109. Jones SN, Hancock AR, Vogel H, Donehower LA, &, Bradley A, (1998) Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 95, 15608-15612.
110. Guo CS, Degnin C, Fiddler TA, Stauffer D, &, Thayer MJ, (2003) Regulation of MyoD activity and muscle cell differentiation by MDM2, pRb, and Sp1. J Biol Chem 278, 22615-22622.
111. Singh RK, Tapia-Santos A, Bebee TW, &, Chandler DS, (2009) Conserved sequences in the final intron of MDM2 are essential for the regulation of alternative splicing of MDM2 in response to stress. Exp Cell Res 315, 3419-3432.
112. Rubin BP, et al,. (2011) Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell 19, 177-191.
113. Hosoyama T, Nishijo K, Prajapati SI, Li G, &, Keller C, (2011) Rb1 gene inactivation expands satellite cell and postnatal myoblast pools. J Biol Chem 286, 19556-19564.
114. Huh MS, Parker MH, Scime A, Parks R, &, Rudnicki MA, (2004) Rb is required for progression through myogenic differentiation but not maintenance of terminal differentiation. J Cell Biol 166, 865-876.
115. Kohashi K, et al,. (2008) Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. J Cancer Res Clin Oncol 134, 1097-1103.
116. De Chiara A, T'Ang A, &, Triche TJ, (1993) Expression of the retinoblastoma susceptibility gene in childhood rhabdomyosarcomas. J Natl Cancer Inst 85, 152-157.
117. Ignatius MS, et al,. (2012) In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Cancer Cell 21, 680-693.